Revolution Medicines’ pan-RAS inhibitor daraxonrasib delivered a major survival benefit in its Phase 3 RASolute 302 trial for metastatic pancreatic ductal adenocarcinoma, beating standard cytotoxic chemotherapy. According to the company, patients on daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months with chemotherapy. The trial included patients with a range of RAS variants, and the primary endpoints targeted patients with RAS G12 mutations. Revolution said it plans to use the data to seek FDA approval, while noting the program’s generally manageable safety profile with no new safety signals. The readout is likely to intensify competitive pressure in pancreatic cancer, where durable options remain limited. The company’s next step is regulatory engagement based on the Phase 3 dataset, setting up a potential accelerated timeline if FDA determines the evidence is sufficient for submission review.